Nancy Holekamp
Ophthalmology · Chesterfield, MONPI 1831197557
Payments from drug & device makers
Across 764 payments — averaging $3551.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$2M
- Regeneron Healthcare Solutions, Inc.$183K
- AbbVie$143K
- F. Hoffmann-la Roche AG$123K
- Genentech USA, Inc.$99K
- Novartis$54K
- plus $148K from 22 others
Across 28 payments — averaging $2247.82 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$58K
- Genentech, Inc.$5K
What the payments were for
- Consulting fees$424,83155%
- Speaking & faculty fees$291,98838%
- Travel & lodging$40,1965%
- Food & beverage$10,0871%
- Education$9190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 285 | $1,964,068 |
| Regeneron Healthcare Solutions, Inc. | 88 | $183,236 |
| AbbVie(2 entities) | 118 | $143,427 |
| F. Hoffmann-la Roche AG | 29 | $122,593 |
| Genentech USA, Inc. | 74 | $98,996 |
| Novartis | 30 | $53,760 |
| Regeneron | 19 | $34,135 |
| Apellis Pharmaceuticals, Inc. | 17 | $31,281 |
| Spark Therapeutics, Inc. | 11 | $17,323 |
| Roche Products Limited | 6 | $14,852 |
| Bausch & Lomb Americas Inc. | 20 | $14,487 |
| Biogen | 4 | $10,644 |
| Alimera Sciences, Inc. | 15 | $7,065 |
| Eyepoint US, Inc. | 11 | $6,961 |
| Boehringer Ingelheim International GmbH | 6 | $4,800 |
| Cardinal Health 108 LLC | 2 | $4,050 |
| Novartis Pharma AG | 1 | $1,050 |
| Notal Vision, Inc. | 1 | $300 |
| Mallinckrodt Hospital Products Inc. | 3 | $189 |
| Sun Pharmaceutical Industries Inc. | 8 | $167 |
| Kala Pharmaceuticals, Inc. | 3 | $56 |
| Alcon | 2 | $34 |
| Sight Sciences, Inc. | 1 | $34 |
| Oyster Point Pharma, Inc. | 2 | $31 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $29 |
| Biotissue Holdings Inc. | 4 | $23 |
| Eyevance Pharmaceuticals LLC | 1 | $14 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EYLEA$206,416
- VABYSMO$77,691
- OZURDEX$67,266
- Lucentis$61,582
- BEOVU$50,919
- SUSVIMO$40,533
- Non-Covered Product$30,877
- LUXTURNA$17,160
- XIPERE$12,383
- YUTIQ$6,795
- Iluvien$3,200
- RTH258A_BEOVU_OPHTHALMOLOGY$1,050
- Foresee Home$300
- ACTHAR$123
How this compares
$2,713,612 in reported general payments places this provider in the 95th percentile of 286 ophthalmology providers in Missouri.
Other ophthalmology in Chesterfield
- Jay PeposeChesterfield$535K
- Mujtaba QaziChesterfield$334K
- Paul TesserChesterfield$29K
- Ibrahim Sayed-AhmedChesterfield$9K
- Steven SilversteinKansas City$1.6M
- Joseph TauberKansas City$1.3M
- Steven CouchSaint Louis$1.2M
- Andrew MoyesKansas City$1.1M
- Ranjan MalhotraSaint Louis$964K
- Navin TekwaniSaint Louis$957K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.